Hims & Hers Health announced on December 10 2025 that it has launched a comprehensive weight‑loss programme in the United Kingdom, pairing its Hers platform for women with prescription access to GLP‑1 therapies such as Wegovy and Mounjaro. The rollout follows the company’s recent acquisition of London‑based telehealth firm Zava, which provides the regulatory and operational infrastructure needed to serve UK patients.
The UK programme offers a doctor‑designed, personalised plan that blends medication, nutrition coaching and behavioural support. Patients can obtain Wegovy and Mounjaro through Hims & Hers’ clinical assessment process, with pricing set at £149 per month for Wegovy and a comparable rate for Mounjaro, positioning the company to capture a share of a market where 64 % of adults are overweight or obese. The inclusion of Orlistat (Orlos) expands the therapeutic options available to consumers.
Strategically, the launch taps a sizeable addressable market and diversifies Hims & Hers’ revenue base beyond the United States. The Zava acquisition, completed earlier in the year for an undisclosed sum, gives the company a ready‑made UK presence and a network of licensed prescribers, enabling rapid scale. Management views the expansion as a key growth lever that complements the company’s broader international scaling strategy, which includes new specialties such as menopause and longevity services.
Financially, the launch comes on the heels of Hims & Hers’ Q3 2025 earnings, where revenue rose 49 % YoY to $599 million, beating analyst expectations of $580.4 million. EPS fell to $0.06 from $0.32 in Q3 2024, a decline driven by higher marketing, technology and general‑administrative expenses that increased 27.4 %, 92.4 % and 80.8 % YoY, respectively. Gross margin contracted from 79 % to 74 % as the company invested heavily in growth initiatives. Despite margin pressure, the company guided for Q4 revenue of $605–$625 million and full‑year 2025 revenue of $2.335–$2.355 billion, signalling confidence that the UK expansion will contribute to sustained top‑line growth.
The competitive landscape in the UK weight‑loss market includes established digital health providers such as MyFitnessPal and traditional pharmacies that offer GLP‑1 therapies. Hims & Hers differentiates itself through a fully integrated digital platform, a streamlined prescription process, and a focus on personalised care. NHS access to Wegovy and Mounjaro remains limited due to high demand and cost constraints, giving Hims & Hers a first‑mover advantage in the private sector. The company’s pricing strategy and partnership with Zava position it to capture patients who would otherwise face long wait times or limited availability.
CEO Andrew Dudum emphasized that the UK launch “expands our reach to a market with a high prevalence of obesity and positions us to deliver evidence‑based care at scale.” CFO Yemi Okupe highlighted that the company’s “strong revenue growth, coupled with disciplined cost management, underpins our confidence in the UK expansion and our broader international strategy.” The company’s guidance for 2026, which includes a projected revenue of $2.335–$2.355 billion and adjusted EBITDA of $307–$317 million, reflects the expected incremental contribution from the UK programme and other new specialties.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.